| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Qijing Bo, Feng Li, Xianbin Li, Zhimin Wang, Fang Dong, Fan He, Anning Li, Xin Ma, Chuanyue Wan. Symptomatic remission in schizophrenia: Results from a risperidone maintenance treatment study. Psychiatry research. vol 258. 2018-05-31. PMID:28865716. |
one-year risperidone maintenance treatment increased remission rates in schizophrenia. |
2018-05-31 |
2023-08-13 |
Not clear |
| Edith J Liemburg, Frank van Es, Henderikus Knegtering, André Alema. Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study. Progress in neuro-psychopharmacology & biological psychiatry. vol 79. issue Pt B. 2018-05-29. PMID:28558941. |
effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: a single-blind randomized exploratory study. |
2018-05-29 |
2023-08-13 |
Not clear |
| Ladan Kashani, Nazila Shams, Ehsan Moazen-Zadeh, Mohammad-Ali Karkhaneh-Yousefi, Gita Sadighi, Mohammad-Reza Khodaie-Ardakani, Farzin Rezaei, Fatemeh Rahiminejad, Shahin Akhondzade. Pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: A randomized double-blind placebo-controlled clinical trial. Journal of psychiatric research. vol 94. 2018-05-28. PMID:28688338. |
pregnenolone as an adjunct to risperidone for treatment of women with schizophrenia: a randomized double-blind placebo-controlled clinical trial. |
2018-05-28 |
2023-08-13 |
human |
| Gabriele Masi, Azzurra Manfredi, Giulia Nieri, Pietro Muratori, Chiara Pfanner, Annarita Milon. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. Journal of clinical psychopharmacology. vol 37. issue 5. 2018-05-07. PMID:28806385. |
we aimed to assess effectiveness and safety of monotherapy with the stimulant methylphenidate (mph) and risperidone in a consecutive sample of 40 drug-naive male youths diagnosed as having adhd-combined presentation, comorbid with odd and aggression, without psychiatric comorbidities, according to the diagnostic and statistical manual of mental disorders, fifth edition criteria and a structured clinical interview (schedule for affective disorders and schizophrenia for school-age children-present and lifetime version). |
2018-05-07 |
2023-08-13 |
Not clear |
| Adriana Foster, Peter Buckley, John Lauriello, Stephen Looney, Nina Schoole. Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. Journal of clinical psychopharmacology. vol 37. issue 5. 2018-05-07. PMID:28806390. |
to explore the effect of switching from ca to monotherapy, we performed an exploratory analysis of the proactive (preventing relapse in schizophrenia: oral antipsychotics compared with injectables: evaluating efficacy) study data, in which 305 patients with schizophrenia and schizoaffective disorder were followed for 30 months after randomization to long-acting injectable (lai) risperidone or second-generation oral antipsychotic (oa). |
2018-05-07 |
2023-08-13 |
Not clear |
| Y Shi, M Li, C Song, Q Xu, R Huo, L Shen, Q Xing, D Cui, W Li, J Zhao, L He, S Qi. Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. Translational psychiatry. vol 7. issue 7. 2018-04-30. PMID:28696411. |
combined study of genetic and epigenetic biomarker risperidone treatment efficacy in chinese han schizophrenia patients. |
2018-04-30 |
2023-08-13 |
Not clear |
| Y Shi, M Li, C Song, Q Xu, R Huo, L Shen, Q Xing, D Cui, W Li, J Zhao, L He, S Qi. Combined study of genetic and epigenetic biomarker risperidone treatment efficacy in Chinese Han schizophrenia patients. Translational psychiatry. vol 7. issue 7. 2018-04-30. PMID:28696411. |
nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia. |
2018-04-30 |
2023-08-13 |
Not clear |
| György Németh, István Laszlovszky, Pál Czobor, Erzsébet Szalai, Balázs Szatmári, Judit Harsányi, Ágota Barabássy, Marc Debelle, Suresh Durgam, István Bitter, Stephen Marder, W Wolfgang Fleischhacke. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet (London, England). vol 389. issue 10074. 2018-04-13. PMID:28185672. |
cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. |
2018-04-13 |
2023-08-13 |
Not clear |
| Suzan Kudlek Mikulic, Alma Mihaljevic-Peles, Marina Sagud, Maja Bajs Janovic, Lana Ganoci, Jasmina Grubisin, Martina Kuzman Rojnic, Bjanka Vuksan Cusa, Zoran Bradaš, Nada Božin. Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic journal of psychiatry. vol 71. issue 7. 2018-04-10. PMID:28671000. |
brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. |
2018-04-10 |
2023-08-13 |
human |
| Suzan Kudlek Mikulic, Alma Mihaljevic-Peles, Marina Sagud, Maja Bajs Janovic, Lana Ganoci, Jasmina Grubisin, Martina Kuzman Rojnic, Bjanka Vuksan Cusa, Zoran Bradaš, Nada Božin. Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic journal of psychiatry. vol 71. issue 7. 2018-04-10. PMID:28671000. |
aim of this study was to investigate the influence of olanzapine or risperidone on both plasma and serum levels of bdnf in patients with acute schizophrenia. |
2018-04-10 |
2023-08-13 |
human |
| Suzan Kudlek Mikulic, Alma Mihaljevic-Peles, Marina Sagud, Maja Bajs Janovic, Lana Ganoci, Jasmina Grubisin, Martina Kuzman Rojnic, Bjanka Vuksan Cusa, Zoran Bradaš, Nada Božin. Brain-derived neurotrophic factor serum and plasma levels in the treatment of acute schizophrenia with olanzapine or risperidone: 6-week prospective study. Nordic journal of psychiatry. vol 71. issue 7. 2018-04-10. PMID:28671000. |
for 50 participants with acute episode of schizophrenia both plasma and serum bdnf, along with the positive and negative syndrome scale (panss) and the clinical global impression scale, were assessed pretreatment and post treatment - after 6 weeks of either risperidone or olanzapine. |
2018-04-10 |
2023-08-13 |
human |
| Farzin Rezaei, Bita Mesgarpour, Alireza Jeddian, Atefeh Zeionoddini, Payam Mohammadinejad, Elaheh Salardini, Mona Shahriari, Arefeh Zeinoddini, Shahin Akhondzade. Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study. Human psychopharmacology. vol 32. issue 4. 2018-04-09. PMID:28421639. |
to evaluate the efficacy and safety of cilostazol, a selective inhibitor of phosphodiesterase iii, as an adjunctive to risperidone in alleviating the negative symptoms of schizophrenia. |
2018-04-09 |
2023-08-13 |
Not clear |
| Vijay Ivaturi, Mathangi Gopalakrishnan, Jogarao V S Gobburu, Weiyan Zhang, Yongzhen Liu, Christian Heidbreder, Celine M Laffon. Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone. British journal of clinical pharmacology. vol 83. issue 7. 2018-04-03. PMID:28133766. |
a new, long-acting, subcutaneous (sc) formulation of risperidone (rbp-7000) has been developed for the treatment of schizophrenia to address issues of non-adherence associated with oral risperidone treatment. |
2018-04-03 |
2023-08-13 |
Not clear |
| Daniel Gabriel, Ewgeni Jakubovski, Jerome H Taylor, Bekir B Artukoglu, Michael H Bloc. Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Psychiatry research. vol 255. 2018-03-20. PMID:28595147. |
the treatment of early-onset schizophrenia spectrum disorders (teoss) compared the efficacy of risperidone, olanzapine, and molindone over 8 weeks in 119 youths age 8-19 years with early-onset schizophrenia or schizoaffective disorder. |
2018-03-20 |
2023-08-13 |
Not clear |
| Ning Fan, Yunlong Tan, Fude Yang, Li Tian, Song Chen, Jia Li, Zhiren Wang, Xiangyang Zhan. Effect of risperidone on serum homocysteine levels in first-episode, drug-naïve patients with schizophrenia. Neuroscience letters. vol 650. 2018-03-19. PMID:28419824. |
effect of risperidone on serum homocysteine levels in first-episode, drug-naïve patients with schizophrenia. |
2018-03-19 |
2023-08-13 |
human |
| Ning Fan, Yunlong Tan, Fude Yang, Li Tian, Song Chen, Jia Li, Zhiren Wang, Xiangyang Zhan. Effect of risperidone on serum homocysteine levels in first-episode, drug-naïve patients with schizophrenia. Neuroscience letters. vol 650. 2018-03-19. PMID:28419824. |
fifty-six first-episode and drug-naïve inpatients with schizophrenia were assigned to a 12-week treatment regime with risperidone. |
2018-03-19 |
2023-08-13 |
human |
| b' J Zhao, Y Zhang, Y Y Chao, J Ma, Y F Yang, J Y Zhao, Y H Du, W W Li, X Q Song, L X L\\xc3\\xb. [Cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia]. Zhonghua yi xue za zhi. vol 96. issue 37. 2018-03-06. PMID:27760654.' |
[cognitive effectiveness of risperidone and olanzapine in first-episode schizophrenia]. |
2018-03-06 |
2023-08-13 |
Not clear |
| Mahfoud Boustta, Michel Ver. A method to slow down the ionization-dependent release of risperidone loaded in a thermoresponsive poly(N-acryloyl glycinamide) hydrogel. Drug delivery and translational research. vol 7. issue 3. 2018-02-15. PMID:28389859. |
risperidone is a weak basic drug sparingly soluble in water frequently used to treat patients suffering of schizophrenia. |
2018-02-15 |
2023-08-13 |
Not clear |
| Taina Mattila, Maarten Koeter, Tamar Wohlfarth, Jitschak Storosum, Wim van den Brink, Eske Derks, Hubertus Leufkens, Damiaan Deny. The impact of second generation antipsychotics on insight in schizophrenia: Results from 14 randomized, placebo controlled trials. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 27. issue 1. 2018-02-12. PMID:27842941. |
the database contained placebo-controlled rcts of five second-generation antipsychotics (sgas: olanzapine, paliperidone, quetiapine, risperidone and sertindole) and included a total of 4243 patients with schizophrenia. |
2018-02-12 |
2023-08-13 |
Not clear |
| Li-Hua Lo, Jentaie Shiea, Tiao-Lai Huan. Rapid detection of alteration of serum IgG in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. Rapid communications in mass spectrometry : RCM. vol 30. issue 24. 2018-02-02. PMID:27699909. |
rapid detection of alteration of serum igg in patients with schizophrenia after risperidone treatment by matrix-assisted laser desorption ionization/time-of-flight mass spectrometry. |
2018-02-02 |
2023-08-13 |
Not clear |